{"id":8817,"date":"2025-09-30T14:04:16","date_gmt":"2025-09-30T11:04:16","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8817"},"modified":"2025-09-30T14:04:16","modified_gmt":"2025-09-30T11:04:16","slug":"cardiogenic-shock-2024-2025-keynotes-from-global-guidelines","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/cardiogenic-shock-2024-2025-keynotes-from-global-guidelines\/","title":{"rendered":"Cardiogenic Shock 2024\u20132025 \u2014 Keynotes from Global Guidelines"},"content":{"rendered":"
Cardiogenic Shock 2024\u20132025 \u2014 Keynotes from Global Guidelines<\/div>\n
<\/div>\n
The most recent international updates on the management of cardiogenic shock (CS) are drawn from the ACC\/AHA Clinical Guidance 2025, ISHLT Consensus 2024, the ESC ACS Update 2023, and the SCAI Shock Staging Framework 2022<\/div>\n
<\/div>\n
Keynotes:<\/div>\n
<\/div>\n
1. Levels of Care (AHA\/ACC \u2013 Heart Failure Centers Framework, adapted for Shock Care)<\/div>\n
\u2022 Level 1 \u2013 Foundation \/ Basic:<\/span><\/div>\n
\u2022 Provides only initial stabilization (fluids, vasopressors, inotropes).<\/span><\/div>\n
\u2022 Basic monitoring and referral pathways.<\/span><\/div>\n
\u2022 Level 2 \u2013 Advanced:<\/span><\/div>\n
\u2022 PCI-capable hospital and short-term possible MCS = Mechanical Circulatory Support devices (IABP, Impella, TandemHeart).<\/span><\/div>\n
\u2022 Can perform emergency revascularization and temporary circulatory support.<\/span><\/div>\n
\u2022 No durable LVAD or transplant programs.<\/span><\/div>\n
\u2022 Level 3 \u2013 Comprehensive \/ Hub:<\/span><\/div>\n
\u2022 High-volume referral center.<\/span><\/div>\n
\u2022 Full advanced therapies: durable LVAD, BiVAD, heart transplantation.<\/span><\/div>\n
\u2022 24\/7 multidisciplinary \u201cShock Team\u201d (cardiology, cardiac surgery, ICU, perfusion).<\/span><\/div>\n
\u2022 Research and training integrated.<\/span><\/div>\n
<\/div>\n
2. ISHLT Consensus (International Society for Heart and Lung Transplantation)<\/div>\n
2024 \u2013 Key Messages:<\/div>\n
\u2022 Cardiogenic shock exists on a continuum, classified by the SCAI stages A\u2013E.<\/span><\/div>\n
\u2022 Stage A: At risk \u2013 patient has acute coronary syndrome or decompensated HF but no shock yet.<\/span><\/div>\n
\u2022 Stage B: Beginning \u2013 early signs of shock (mild hypotension, tachycardia).<\/span><\/div>\n
\u2022 Stage C: Classic \u2013 clear hypotension with hypoperfusion (cold extremities, oliguria, high lactate).<\/span><\/div>\n
\u2022 Stage D: Deteriorating \u2013 worsening shock despite fluids, vasopressors, or inotropes.<\/span><\/div>\n
\u2022 Stage E: Extremis \u2013 circulatory collapse or cardiac arrest.<\/span><\/div>\n
<\/div>\n
Treatment intensity must match severity: simple support in early stages, escalating to advanced therapies and MCS in later stages.<\/div>\n
<\/div>\n
\u2022 Checklists before transfer (vitals, labs, echo, therapies, shock stage) save critical time.<\/span><\/div>\n
\u2022 End-organ perfusion (brain, kidney, liver) is the ultimate therapeutic goal\u2014not a fixed blood Bp target.<\/span><\/div>\n
\u2022 Anticoagulation with temporary MCS must be individualized:<\/span><\/div>\n
\u2022 Impella: continuous heparin flush through the device + systemic anticoagulation.<\/span><\/div>\n
\u2022 ECMO: continuous IV heparin with ACT\/aPTT monitoring.<\/span><\/div>\n
\u2022 Timing: highest thrombus risk during the first 24\u201348 hours after device insertion.<\/span><\/div>\n
<\/div>\n
3. ACC\/AHA 2025 Guidelines \u2014 ACS and Cardiogenic Shock<\/div>\n
<\/div>\n
STEMI (ST-elevation MI)<\/div>\n
\u2022 Immediate transfer to a PCI-capable hospital (Class I,B).<\/span><\/div>\n
\u2022 Primary PCI is recommended irrespective of symptom duration if cardiogenic shock or ongoing ischemia is present (Class I, ,B)<\/span><\/div>\n
\u2022 CABG if PCI is not feasible (Class I\u00a0 ,B)<\/span><\/div>\n
\u2022 Fibrinolysis if neither PCI nor CABG is available (Class I,\u00a0 \ud83d\ude0e<\/span><\/div>\n
\u2022 Beta blockers contraindicated in shock.<\/span><\/div>\n
\u2022 IABP: Routine use not recommended; selective use may be considered if the patient does not stabilize with drugs and no other temporary advanced MCS (Impella, TandemHeart, VA-ECMO) is available.<\/span><\/div>\n
\u2022 In many Level 1\u20132 centers, IABP remains the only feasible bridge until transfer to a Level 3 hub.<\/span><\/div>\n
\u2022 Durable LVADs are not acute rescue devices; they are for long-term MCS or bridge-to-transplant strategies.<\/span><\/div>\n
<\/div>\n
NSTEMI (Non-ST-elevation MI)<\/div>\n
\u2022 Less frequent association with shock compared to STEMI, but equally critical.<\/span><\/div>\n
\u2022 Early invasive strategy with revascularization is recommended (Class I ,B).<\/span><\/div>\n
\u2022 Beta blockers contraindicated when shock risk is present.<\/span><\/div>\n
\u2022 IABP may be reasonable in refractory shock if other options are not available (Class IIa, C).<\/span><\/div>\n
<\/div>\n
CCS (Chronic Coronary Syndromes)<\/div>\n
\u2022 Cardiogenic shock in CCS is rare.<\/span><\/div>\n
\u2022 When it occurs, it is usually due to a superimposed acute event, such as:<\/span><\/div>\n
\u2022 New myocardial infarction (STEMI or NSTEMI).<\/span><\/div>\n
\u2022 Mechanical complication (acute MR from papillary muscle rupture, VSD, free wall rupture).<\/span><\/div>\n
\u2022 Severe arrhythmias or decompensation in advanced LV dysfunction.<\/span><\/div>\n
\u2022 In such cases, patients should be managed as ACS with shock until proven otherwise.<\/span><\/div>\n
\u2022 Urgent ECG, echocardiography, and transfer to a PCI-capable center are essential.<\/span><\/div>\n
<\/div>\n
Key Point:<\/div>\n
\u2022 STEMI & NSTEMI with shock \u2192 require immediate revascularization and tailored MCS support.<\/span><\/div>\n
\u2022 CCS with shock \u2192 almost always reflects an acute transition to ACS or a complication, so it must be managed as ACS.<\/span><\/div>\n
<\/div>\n
4. ESC 2023 ACS Guidelines \u2014 Cardiogenic Shock<\/div>\n
\u2022 Routine IABP not recommended (Class III)<\/span><\/div>\n
\u2022 Short-term MCS may be considered in refractory shock (Class IIb, C).<\/span><\/div>\n
\u2022 Priorities:<\/span><\/div>\n
\u2022 Rapid transfer to a center with cath lab (for PCI capability).<\/span><\/div>\n
\u2022 Immediate ECG and echocardiography.<\/span><\/div>\n
\u2022 Continuous ECG and invasive BP monitoring.<\/span><\/div>\n
\u2022 Coronary angiography as soon as possible (in shock: immediate, not bound to 90 minutes only).<\/span><\/div>\n
\u2022 Fluids: only if no pulmonary congestion.<\/span><\/div>\n
\u2022 Dobutamine: for low cardiac output when SBP \u226585\u201390 mmHg.<\/span><\/div>\n
\u2022 Norepinephrine: preferred vasopressor if SBP <85 mmHg or persistent hypoperfusion.<\/span><\/div>\n
\u2022 Dopamine discouraged due to risk of arrhythmias.<\/span><\/div>\n
<\/div>\n
5.MCS Expert Consensus (SCAI\/ACC\/HFSA\/STS 2015)<\/div>\n
\u2022 IABP and ECMO were historical first-line devices.<\/span><\/div>\n
\u2022 Impella and TandemHeart provide stronger hemodynamic support than IABP.<\/span><\/div>\n
\u2022 Early MCS placement should be considered if no improvement with initial drugs.<\/span><\/div>\n
\u2022 VA-ECMO supports both circulation and oxygenation; useful when shock + respiratory failure coexist.<\/span><\/div>\n
\u2022 Right ventricular shock may need targeted RV support.<\/span><\/div>\n
<\/div>\n
6. ISHLT (International Society for Heart and Lung Transplantation) 2024 \u2014 Long-Term Mechanical Circulatory Support (MCS) Guidance:<\/div>\n
\u2022 Durable LVAD indicated if:<\/span><\/div>\n
\u2022 Ventricular function unrecoverable.<\/span><\/div>\n
\u2022 Failure to wean from temporary MCS\/inotropes.<\/span><\/div>\n
\u2022 End-organ recovery possible.<\/span><\/div>\n
\u2022 No irreversible organ damage.<\/span><\/div>\n
<\/div>\n
7. Pharmacologic Management<\/div>\n
\u2022 Vasopressors: norepinephrine is first-line; avoid dopamine.<\/span><\/div>\n
\u2022 Inotropes: dobutamine or milrinone if low cardiac output.<\/span><\/div>\n
\u2022 Vasodilators: IV nitroglycerin (avoid in hypotension).<\/span><\/div>\n
\u2022 Antiplatelets: aspirin early in ACS\/shock.<\/span><\/div>\n
\u2022 Analgesia: morphine reduces pain and sympathetic stress.<\/span><\/div>\n
\u2022 Diuretics: furosemide if pulmonary congestion present.<\/span><\/div>\n
\u2022 Other: nesiritide possible but hypotension risk limits use.<\/span><\/div>\n
<\/div>\n
Key Takeaway :<\/div>\n
\u2022 Levels of Care (1\u20133, AHA): Level 3 centers provide the highest, most comprehensive therapy including LVAD and transplant.<\/span><\/div>\n
\u2022 Early revascularization (PCI\/CABG) remains cornerstone therapy.<\/span><\/div>\n
\u2022 Norepinephrine is the preferred vasopressor; dopamine discouraged.<\/span><\/div>\n
\u2022 Routine IABP no longer recommended; use modern MCS (Impella, ECMO) early if shock persists.<\/span><\/div>\n
\u2022 Focus on end-organ perfusion, not just blood pressure.<\/span><\/div>\n
\u2022 Multidisciplinary shock teams and systematic transfer to higher levels are essential for survival.<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

Cardiogenic Shock 2024\u20132025 \u2014 Keynotes from Global Guidelines The most recent international updates on the management of cardiogenic shock (CS) are drawn from the ACC\/AHA Clinical Guidance 2025, ISHLT Consensus 2024, the ESC ACS Update 2023, and the SCAI Shock Staging Framework 2022 Keynotes: 1. Levels of Care (AHA\/ACC \u2013 Heart Failure Centers Framework, adapted […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8817","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8817"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8817\/revisions"}],"predecessor-version":[{"id":8818,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8817\/revisions\/8818"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}